Tema Heart & Health ETF (HRTS)

The Tema Heart & Health ETF (HRTS) invests in a global portfolio of firms advancing heart health and related wellness, spanning medical-device makers, biotechnology companies, diagnostics firms, and digital-health platforms. Tema is a thematic-investing specialist, and HRTS reflects its thesis that treating and preventing cardiovascular disease will drive capital flows and innovation for decades.

The theme and its scope

Heart disease remains a leading cause of death globally. The aging of wealthy-nation populations, rising prevalence of risk factors like obesity and diabetes, and advancing technology all point toward sustained demand for new treatments, monitoring devices, surgical tools, and data analytics. Tema’s view is that this creates a structural opportunity for companies helping to prevent, detect, and treat heart disease — from the pharmaceutical researcher to the hospital equipment supplier to the app maker tracking patient vitals.

HRTS casts a wide net. Holdings span large-cap medical-device manufacturers, mid-cap biotechnology companies working on heart drugs, private-equity-backed medical-device startups preparing IPOs, and small diagnostic-imaging firms. Some holdings are household names in healthcare; others are obscure to retail investors. The common thread is contribution to cardiovascular care: reducing heart-attack risk, improving surgical outcomes, extending life post-diagnosis, or enabling patients to manage conditions at home.

The fund includes international holdings as well as US firms. Europe and developed Asia have strong medical-device and biotech industries, and Tema draws from these markets. This adds currency exposure — a minor consideration for US-based investors but a real one over multi-year periods.

Portfolio construction and thematic screening

Tema does not track an index. Instead, a team of thematic analysts identifies companies in the heart-health ecosystem and applies financial screens to ensure they are substantial and investable — typically a market capitalization of at least US$200 million to $500 million, adequate trading volume, and financial transparency. Once screened, holdings are weighted roughly equally or with a mild lean toward larger names. Portfolio concentration varies but is typically moderate — no single holding exceeds 2% to 3% of the fund, and the top ten or twenty holdings make up 20% to 40% of assets.

The thematic framing allows Tema to hold both old and new companies. A century-old surgical-instrument maker and a five-year-old wearable-monitoring startup might both qualify if both are advancing cardiovascular care. This diversity of company life stages and maturity is both a strength and a weakness: it captures innovation early but also exposes the portfolio to startups with limited operating histories.

Tema rebalances quarterly or semi-annually. As companies grow, get acquired, or fall out of favor, portfolio weights adjust. If a holding is acquired or merges out of existence, it is replaced with another thematic match.

Costs and liquidity

HRTS carries an expense ratio of roughly 0.75% to 0.90% annually — higher than passive broad-market funds (0.03% to 0.20%) but reasonable for a specialized, actively managed thematic fund. The cost is justified by the research required to identify thematic holdings and the ongoing rebalancing.

Trading volume in HRTS is modest but adequate. Bid-ask spreads typically run 0.15% to 0.30%, making the fund economical for moderate position sizes. Daily volume has grown as the fund has matured, but it remains thinly traded relative to large broad-market ETFs. Investors should avoid large single purchases or sales that might move the market.

Risks particular to thematic investing

Thematic funds are more volatile than the broad market and more concentrated in a specific narrative. HRTS benefits when heart-health innovation is in favor, capital is flowing toward medical technology, and regulatory environments are supportive. It suffers when the opposite is true — when technology disappointments emerge, regulatory setbacks occur, or capital markets freeze and private companies can no longer reach IPO windows.

The theme itself may evolve. Cardiovascular disease remains a huge health burden, but funding and innovation priorities shift. If political pressure, funding constraints, or scientific breakthroughs redirect resources toward cancer or neurodegenerative disease, HRTS’s focus would become less central to biotech capital flows. This is not imminent, but it is a real long-term risk in any thematic fund.

Smaller holdings within HRTS carry company-specific risks typical of mid-cap and small-cap stocks. A promising biotech might announce a failed drug trial. A device maker might face unexpected regulatory hurdles. These events can sink an individual holding even as the broader heart-health theme prospers. Diversification across 50+ or 100+ holdings mitigates single-stock risk, but it does not eliminate it.

Who owns HRTS and how to research it

HRTS appeals to thematic or impact-focused investors who want to own companies working on specific global challenges rather than own the market broadly. It suits investors with a three-to-ten-year horizon who can tolerate sector-style volatility and understand that thematic tilts will periodically lag the wider market.

It is less suitable for investors seeking low costs, broad diversification, or maximum simplicity. Passive investors can achieve similar health-sector exposure far more cheaply with a passive healthcare ETF. Conservative investors might find the concentration risk uncomfortable.

Prospective buyers should read HRTS’s prospectus and review its current holdings — Tema publishes these regularly. Cross-referencing holdings against news (FDA approvals, clinical trials, acquisitions, earnings) helps frame whether the portfolio is current and well-researched. Speaking with Tema’s analysts about the investment process and outlook on cardiovascular innovation is worthwhile for significant allocations.